Toronto, Ontario, April 07, 2017 (GLOBE NEWSWIRE) -- Luminar Media Group, Inc., (Luminar, OTCMKTS: LRGR) and The Jenex Corporation (Jenex, NEX: JEN.H) report the completion of a working prototype for the patent pending TherOZap™ device. An Agreement has been signed with the University Health Network to test Therozap™ against the Zika and West Nile viruses.
Chris Cook, CEO and Chairman of Luminar Media Group, Inc., (Luminar, OTCMKTS: LRGR), and global licensee for TherOZap™ outside of Canada comments: “The availability of a working prototype brings us one step closer to releasing this product to market. Expanding the device's effectiveness to the Zika and West Nile virus will provide tremendous benefit for many regions of the world.” Images of the Therozap™ prototype can be viewed at www.therozap.com .
Jenex has optimized the features on the TherO Zap ™ working prototype device as protection against both the Zika virus and West Nile virus and potentially other mosquito borne diseases. Jenex has signed an agreement with University Health Network (“UHN”) to initiate testing of the TherO Zap ™ device against these viruses. Over the next several weeks Jenex will be coordinating with the Techna Institute at UHN to devise the protocols for the initial tests. It is anticipated that once all testing is complete, Jenex will commercialize TherOZap™, pending regulatory approval where required.
Rob Fia, CEO commented, “We are very excited with the TherO Zap ™ working prototype. Jenex looks forward to working with UHN to begin the initial testing to determine the effectiveness of the device at inactivating both the Zika and West Nile viruses."
About Jenex
Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs. Clear and healthy skin for all is at the core of Jenex’s philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments. The Company's breakthrough proprietary thermal therapy technology uses heat and light energy to deliver effective, non-invasive and pain free skin care. Jenex received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). Jenex received approval for the above claims from FDA (United States) in 1997.The Jenex Corporation trades on the NEX (NEX: JEN.H). For more information visit: www.thejenexcorporation.com or www.interceptcs.com
About Techna Institute:
Techna is an institute of the University Health Network, in collaboration with the University of Toronto, focused on the accelerated development and exploitation of technology for improved health. Techna is designed to shorten the time interval from technology discovery and development to application for the benefit of patients and the health care system. It also stimulates and facilitates the innovation cycle through a continuum of clinically driven innovation, technology & process development, and translational research. For more information visit: technainstitute.com
About University Health Network:
University Health Network (UHN) is a major landmark in Canada’s healthcare system and a teaching partner of the University of Toronto. UHN consists of Toronto General and Toronto Western Hospitals, the Princess Margaret Cancer Centre, Toronto Rehabilitation Institute and the Michener Institute for Education at UHN. The scope of research and complexity of cases at University Health Network has made it a national and international source for discovery, education and patient care. It has the largest hospital-based research program in Canada, with major research in cardiology, transplantation, neurosciences, oncology, surgical innovation, infectious diseases, genomic medicine and rehabilitation medicine. For more information visit: www.uhn.ca
About Luminar:
The Luminar Media Group has extensive knowledge and experience in the media, marketing and entertainment industries. Luminar will bring this expertise to the TherOZap trade name and is developing a global marketing strategy. Initial efforts will focus on launching its innovative therapy device in the United States with additional markets to follow closely. The company was started by entrepreneurs who can identify new tools to communicate with a target audience. At Luminar, we embrace the challenge of the constantly evolving business landscape and our determined culture will develop solutions that evolve with the changing business paradigm.
Forward-Looking Statements
This news release contains forward-looking statements about our business, or financial condition and prospects, that reflect our assumptions and beliefs based on information currently available. The Company can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this news release, words such as "believes," "expects," "intends," "plans," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements, although there may be certain forward-looking statements not accompanied by such expressions. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including risks discussed in the company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( www.sec.gov ). All forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by these factors other than as required under the securities laws. The Company does not assume a duty to update these forward-looking statements.
Investors should refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.
Luminar Media Group Investor Relations Email: ir@gdee.rocks Website: www.gdee.rocks , http://www.luminarinc.com/ Source: Luminar Media Group, Inc.
